McKesson reported a strong third quarter for FY2025, driven by robust growth in the U.S. Pharmaceutical segment and the Prescription Technology Solutions (RxTS) platform. Revenue rose 18% year-over-year to $95.3 billion, with adjusted operating profit up 16% to $1.5 billion, reflecting broad-based strength across three of four segments. U.S. Pharmaceutical benefited from higher prescription volumes and continued momentum in specialty product distribution, including GLP-1 medications, while RxTS benefited from greater access and affordability solutions. The Medical-Surgical Solutions (Med-Surg) segment, by contrast, faced softer volumes tied to a milder illness season and lower primary care foot traffic, dampening near-term performance in that unit. Management underscored strategic actions to rationalize underperforming assets and invest in high-growth platforms, including oncology and biopharma services, retina/ophthalmology, and clinical trial services via SCRI. McKesson narrowed and raised its full-year guidance for fiscal 2025: adjusted EPS now targeted at $32.55–$32.95, implying roughly 19–20% year-over-year growth, with expected incremental revenue from a strategic partner approaching $32 billion in full-year 2025. The company also disclosed the PRISM Vision acquisition (80% stake for about $850 million), signaling an accelerated expansion in Retina/Ophthalmology alongside its existing retina assets (Onmark Vision, Retina OS). Near-term cash flow remained pressured by working capital movements, with negative quarterly free cash flow of approximately $2.58 billion, though the full-year free cash flow guidance remains intact at $4.8–$5.2 billion. Looking ahead, McKesson reiterated a long-term EPS growth target of 12–14% and signaled ongoing investments in AI, data analytics, and North American distribution modernization to sustain competitive advantages across its diverse platform.